what is the difference between glp 1 and zepbound Comparing Ozempic, Wegovy Other GLP-1 Drugs Trouble getting weight loss drugs

To view or add a comment, sign in Samjin Pharmaceutical applies for domestic Phase 1 clinical trials of novel inflammation and immunology drug candidate SJN314 Samjin Pharmaceutical (hereinafter referred to as Samjin Pharm) announced on February 4 that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1 clinical trial of SJN314 (development code). The candidate represents a key asset within the company's novel drug research pipeline focused on Inflammation & Immunology. SJN314 is an orally administered, small-molecule inhibitor of Mas-related G-protein-coupled receptor X2 (MRGPRX2), being developed for the treatment of inflammatory conditions such as chronic spontaneous urticaria (CSUR) and atopic dermatitis

126 SulhanS.LyonK

It helps with signaling and cell growth

Enzyme and pH dual-responsive CAP@ CS@ PLGA microcapsules for controlled release antibacterial application